Literature DB >> 10348772

Piperacillin and tazobactam exhibit linear pharmacokinetics after multiple standard clinical doses.

B Auclair1, M P Ducharme.   

Abstract

A population pharmacokinetic (PK) analysis was conducted to determine if piperacillin and tazobactam exhibited linear or nonlinear PKs and if incremental changes in the daily dosage of piperacillin affected tazobactam PKs. Four dosage groups were evaluated after multiple dosing regimens. Concentrations of drug in plasma and amounts in urine were best fitted by using a linear two-compartment PK model. No significant difference between dosing groups was seen for any piperacillin or tazobactam PK parameters. Both drugs exhibited linear PKs when given at usual clinical doses. Tazobactam PKs did not appear to be affected by the different dosing regimens of piperacillin.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10348772      PMCID: PMC89298          DOI: 10.1128/AAC.43.6.1465

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

1.  Pharmacokinetics and pharmacodynamics of two multiple-dose piperacillin-tazobactam regimens.

Authors:  D J Occhipinti; S L Pendland; L L Schoonover; E B Rypins; L H Danziger; K A Rodvold
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

2.  Dose dependence of piperacillin pharmacokinetics.

Authors:  T Bergan; J D Williams
Journal:  Chemotherapy       Date:  1982       Impact factor: 2.544

3.  Pharmacokinetics of piperacillin following intravenous administration.

Authors:  M A Evans; P Wilson; T Leung; J D Williams
Journal:  J Antimicrob Chemother       Date:  1978-05       Impact factor: 5.790

4.  Comparison of the pharmacokinetic and pharmacodynamic activity of piperacillin and mezlocillin.

Authors:  M C Sullivan; C H Nightingale; R Quintiliani; K Sweeney
Journal:  Pharmacotherapy       Date:  1993 Nov-Dec       Impact factor: 4.705

5.  Piperacillin: human pharmacokinetics after intravenous and intramuscular administration.

Authors:  T B Tjandramaga; A Mullie; R Verbesselt; P J De Schepper; L Verbist
Journal:  Antimicrob Agents Chemother       Date:  1978-12       Impact factor: 5.191

6.  Single-dose pharmacokinetics of piperacillin and tazobactam in infants and children.

Authors:  M D Reed; J Goldfarb; T S Yamashita; E Lemon; J L Blumer
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

7.  Piperacillin kinetics.

Authors:  V K Batra; J A Morrison; K C Lasseter; V A Joy
Journal:  Clin Pharmacol Ther       Date:  1979-07       Impact factor: 6.875

8.  The effect of piperacillin dose on elimination kinetics in renal impairment.

Authors:  G R Aronoff; R S Sloan; M E Brier; F C Luft
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

9.  Pharmacokinetics of piperacillin in subjects with various degrees of renal function.

Authors:  P G Welling; W A Craig; R W Bundtzen; F W Kwok; A U Gerber; P O Madsen
Journal:  Antimicrob Agents Chemother       Date:  1983-06       Impact factor: 5.191

Review 10.  Piperacillin/tazobactam: a new beta-lactam/beta-lactamase inhibitor combination.

Authors:  L L Schoonover; D J Occhipinti; K A Rodvold; L H Danziger
Journal:  Ann Pharmacother       Date:  1995-05       Impact factor: 3.154

View more
  6 in total

1.  Pharmacokinetics of piperacillin-tazobactam in anuric intensive care patients during continuous venovenous hemodialysis.

Authors:  Silke C Mueller; Jolanta Majcher-Peszynska; Heiko Hickstein; Astrid Francke; Annette Pertschy; Martin Schulz; Ralf Mundkowski; Bernd Drewelow
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

2.  Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation.

Authors:  Thomas P Lodise; Ben Lomaestro; Keith A Rodvold; Larry H Danziger; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

3.  Continuous versus intermittent piperacillin/tazobactam infusion in infection due to or suspected pseudomonas aeruginosa.

Authors:  Jesús Cotrina-Luque; Maria Victoria Gil-Navarro; Héctor Acosta-García; Eva Rocío Alfaro-Lara; Rafael Luque-Márquez; Margarita Beltrán-García; Francisco Javier Bautista-Paloma
Journal:  Int J Clin Pharm       Date:  2016-02

4.  Population pharmacokinetic analysis of nonlinear behavior of piperacillin during intermittent or continuous infusion in patients with cystic fibrosis.

Authors:  Alexander A Vinks; Jan G Den Hollander; Shelley E Overbeek; Roger W Jelliffe; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

5.  Population pharmacokinetics of extended-infusion piperacillin-tazobactam in hospitalized patients with nosocomial infections.

Authors:  T W Felton; W W Hope; B M Lomaestro; J M Butterfield; A L Kwa; G L Drusano; T P Lodise
Journal:  Antimicrob Agents Chemother       Date:  2012-05-14       Impact factor: 5.191

6.  Pharmacokinetics of piperacillin/tazobactam in cancer patients with hematological malignancies and febrile neutropenia after chemotherapy.

Authors:  José C Álvarez; Sonia I Cuervo; Javier R Garzón; Julio C Gómez; Jorge Augusto Díaz; Edelberto Silva; Ricardo Sánchez; Jorge A Cortés
Journal:  BMC Pharmacol Toxicol       Date:  2013-11-28       Impact factor: 2.483

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.